| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_16.12 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_56.10 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_69.11 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_04.83 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_60.84 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_77.82 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_31.46 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_33.47 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_59.48 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_15.118 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_32.119 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_76.120 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_37.154 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_57.155 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_58.156 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_11.191 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_39.192 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_40.190 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_01.BLANK.1 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_02.POOL.1 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_20.BLANK.2 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_21.POOL.2 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_42.BLANK3 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_43.POOL.3 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_62.BLANK.4 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_63.POOL.4 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_81.BLANK.5 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_82.POOL.5 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_47.1 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_52.3 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_71.2 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_07.73 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_12.74 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_30.75 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_05.39 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_09.38 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_27.37 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_10.111 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_25.110 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_53.109 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_18.146 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_51.145 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_72.147 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_38.183 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_67.181 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase POSITIVE ION MODE | LIPPOS17MAR_70.182 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_16.12 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_56.10 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_69.11 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_60.84 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_77.82 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_83.83 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_31.46 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_33.47 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_59.48 | Treatment_Status:Atorvastatin | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_15.118 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_32.119 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_76.120 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_37.154 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_57.155 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_58.156 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_11.191 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_39.192 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_40.190 | Treatment_Status:Atorvastatin | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_01.BLANK.1 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_02.POOL.1 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_20.BLANK.2 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_21.POOL.2 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_42.BLANK3 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_43.POOL.3 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_62.BLANK.4 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_63.POOL.4 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_89.BLANK.5 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_90.POOL.5 | Treatment_Status:N/A | MDM2 Amplification:N/A | Cell line:N/A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_47.1 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_52.3 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_71.2 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:141 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_07.73 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_12.74 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_30.75 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:224A | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_09.38 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_27.37 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_84.39 | Treatment_Status:Untreated | MDM2 Amplification:Higher | Cell line:246 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_10.111 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_25.110 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_53.109 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:224B | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_18.146 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_51.145 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_72.147 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:815 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_38.183 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_67.181 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:863 | ppm |
| Reversed phase NEGATIVE ION MODE | LIPNEG17MAR_70.182 | Treatment_Status:Untreated | MDM2 Amplification:Lower | Cell line:863 | ppm |
Return to study ST001405 main page
Download data matrix(MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models Reversed phase POSITIVE ION MODE)
Download data matrix(MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models Reversed phase NEGATIVE ION MODE)
- Metabolomics Workbench
|